Is treatment with liraglutide efficient?;¿Es eficiente el tratamiento con liraglutida?

Endocrinologia y Nutricion

Volumn 61, Issue 4, 2014, Pages 202-208

  Mezquita Raya, Pedro ^a,b   Reyes García, Rebeca ^b,c  

^a Unidad de Endocrinología Nutrición y Riesgo Vascular Complejo Hospitalario Torrecárdenas   (Spain)

^b Servicio de Endocrinología Clínica San Pedro   (Spain)

^c Unidad de Endocrinología HGU Rafael Méndez   (Spain)

Author keywords

Cost effectiveness; Liraglutide; National Institute for Health and Clinical Excellence; Type 2 diabetes mellitus

Indexed keywords

LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ALTERNATIVE MEDICINE; CARDIOVASCULAR RISK; CLINICAL INDICATOR; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; COMPLICATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897059942     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2013.09.001     Document Type: Short Survey

References (42)

1. Soriguer F., Goday A., Bosch-Comas A., Bordiu E., Calle-Pascual A., Carmena R., et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia 2012, 55:88-93.
2. Olveira-Fuster G., Olvera-Marquez P., Carral-Sanlaureano F., Gonzalez-Romero S., Aguilar-Diosdado M., Soriguer-Escofet F. Excess hospitalizations, hospital days, and inpatient costs among people with diabetes in Andalusia, Spain. Diabetes Care 2004, 27:1904-1909.
3. Barnett A.H. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab 2012, 14:304-314.
4. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
5. Victoza. Summary of Product Characteristics. European Medicines Agency [actualizado 26 Nov 2012; consultado 5 Ag 2013]. Disponible en: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf.
6. Misurski D., Lage M.J., Fabunmi R., Boye K.S. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009, 7:245-254.
7. Davies M.J., Chubb B.D., Smith I.C., Valentine W.J. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med 2012, 29:313-320.
8. Mata M., Antonanzas F., Tafalla M., Sanz P. El coste de la diabetes tipo 2 en España. El estudio CODE-2. Gac Sanit 2002, 16:511-520.
9. Mata-Cases M., Casajuana M., Mauricio D., Morros R., Hermosilla E., Fina F., et al. El coste de la diabetes tipo 2: resultados de un estudio poblacional en Catalunya. XXIV Congreso de la Sociedad Española de Diabetes 2013, 77. Sevilla.
10. Oliva J., Lobo F., Molina B., Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004, 27:2616-2621.
11. Lopez Bastida J., Serrano Aguilar P., Duque Gonzalez B. Los coste socioeconómicos de la diabetes mellitus. Aten Primaria 2002, 29:145-150.
12. Ballesta M., Carral F., Olveira G., Giron J.A., Aguilar M. Economic cost associated with type II diabetes in Spanish patients. Eur J Health Econ 2006, 7:270-275.
13. Lopez-Bastida J., Boronat M., Moreno J.O., Schurer W. Costs, outcomes and challenges for diabetes care in Spain. Global Health 2013, 9:17.
14. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
15. Rodriguez A., Calle A., Vazquez L., Chacon F., Polavieja P., Reviriego J. Blood glucose control and quality of health care in non-insulin-treated patients with Type 2 diabetes in Spain: a retrospective and cross-sectional observational study. Diabet Med 2011, 28:731-740.
16. Chiu C.J., Wray L.A. Factors predicting glycemic control in middle-aged and older adults with type 2 diabetes. Prev Chronic Dis 2010, 7:A08.
17. Cryer P.E. Hypoglycaemia: the limiting factor in the glycaemic management of type i and type II diabetes. Diabetologia 2002, 45:937-948.
18. Khunti K., Damci T., Meneghini L., Pan C.Y., Yale J.F. Study of Once Daily Levemir (SOLVE): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab 2012, 14:654-661.
19. Home P.D. Impact of the UKPDS-an overview. Diabet Med 2008, 25(Suppl 2):2-8.
20. Gisbert R., Brosa M. Base de datos de costes sanitarios 1997-2004 [CD-ROM] 2004, Centro de Estudios en Economía de la Salud y Política Social, Barcelona.
21. Menéndez Torre E., Tartón García T., Ortega Millán C., Fornos Pérez J., García Mayor R., López Fernández M. Recomendaciones 2012 de la Sociedad Española de Diabetes sobre la utilización de tiras reactivas para la medición de la glucemia capilar en personas con diabetes. Av Diabetol 2012, 28:3-9.
22. European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). Investigation into GLP-1 based diabetes therapies concluded. No new concerns for GLP-1 therapies identified on the basis of available evidence. 2013 [actualizado 26 Jul 2013; consultado 5 Ag 2013]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1.
23. Ministerio de Sanidad y Consumo. Guía de práctica clínica en la diabetes tipo 2 [portal de internet]. Vitoria-Gasteiz: MSC [actualizado Jul 2008; citado 5 Ag 2013]. Disponible en: http://www.guiasalud.es/GPC/GPC_429_Diabetes_2_Osteba_compl.pdf.
24. Marre M., Shaw J., Brandle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
25. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
26. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
27. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
28. Wang B., Zhong J., Lin H., Zhao Z., Yan Z., He H., et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials. Diabetes Obes Metab 2013, 15:737-749.
29. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
30. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
31. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
32. Davies M., Lavalle-Gonzalez F., Storms F., Gomis R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008, 10:387-399.
33. Palmer A.J., Roze S., Valentine W.J., Minshall M.E., Foos V., Lurati F.M., et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004, 20(Suppl 1):S5-S26.
34. Sacristan J.A., Oliva J., del Llano J., Prieto L., Pinto J.L. [What is an efficient health technology in Spain?]. Gac Sanit 2002, 16:334-343.
35. Ebrahim S., Davey Smith G., McCabe C., Payne N., Pickin M., Sheldon T.A., et al. What role for statins? A review and economic model. Health Technol Assess 1999, 3:1-91.
36. National Institute for Health and Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. Londres: NICE; 2010 [actualizado Oct 2010; citado 5 Ag 2013]. Disponible en: http://guidance.nice.org.uk/TA203.
37. Hermansen K., Kolotkin R.L., Hammer M., Zdravkovic M., Matthews D. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Prim Care Diabetes 2010, 4:113-117.
38. Davies M., Pratley R., Hammer M., Thomsen A.B., Cuddihy R. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011, 28:333-337.
39. Jendle J., Torffvit O., Ridderstrale M., Lammert M., Ericsson A., Bogelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010, 26:917-923.
40. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
41. Zinman B., Schmidt W.E., Moses A., Lund N., Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012, 14:77-82.
42. Ministerio de Sanidad, Servicios Sociales e Igualdad. Información sobre los productos incluidos en la prestación farmacéutica del SNS (dispensables a través de oficinas de farmacia). Nomenclator de Facturación [consultado 5 Ag 2013]. Disponible en: http://www.msc.es/profesionales/nomenclator.do.